Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)
CALCAGNO, Andrea;
2015-01-01
Abstract
Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
9 Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure.pdf
file disponibile solo agli amministratori
Licenza:
DRM non definito
Dimensione
187.65 kB
Formato
Adobe PDF
|
187.65 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
